International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

About the trial

Sponsor

Sanofi

Tested

Isatuximab intravenous (IV) (drug), Cemiplimab (SAR439684) (drug), Dexamethasone (drug), Lenalidomide (drug), Pomalidomide (drug), Isatuximab subcutaneous (SC) (drug), Carfilzomib (drug)

Dates

Started 2023-04-05; completion 2028-11-30

Results posted

Not yet

* This is a multi-center, open-label, Phase 2 treatment extension study in participants with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study. * This Treatment Extension study has the purpose to provide continued access to isatuximab. Adult participants with multiple myeloma who have enrolled on an isatuximab parental study for which study objectives are completed will be eligible to be enrolled in this Treatment Extension study. * The primary objective of the study is to assess long-term safety of isatuximab as study treatment.

From ClinicalTrials.gov, last updated 2026-10-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $35,735 in research payments for this study in 2025 (6 payments).

Products named: Sarclisa

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.